Thirty-two @entity1 and adolescents received their renal transplant at the Montefiore Medical Center, in New York, between October 1996 and May 2000. Twenty-four @entity1 received basiliximab, in addition to @entity1140 and @entity230 (basiliximab group). The remaining eight @entity1 received only @entity1140 and @entity230 (non-basiliximab group). The 1-year @entity1 survival rate was 100% in both groups. The 1-year graft survival rate was 87.5% for the basiliximab group and 75% for the non-basiliximab group (P=0.45). The rates of acute rejection in the basiliximab and non-basiliximab groups were 26% and 43%, respectively (P=0.36). However, in recipients with <or=3 HLA mismatches, the rate of acute rejection was zero in the basiliximab group, and 40% in the non-basiliximab group (P=0.04). The beneficial effect occurred despite the fact that @entity1140 was maintained at below the target levels. There were no adverse events directly attributable to the administration of basiliximab. There were no cases of @entity1292 or @entity1071 . In summary, addition of basiliximab to @entity1140 and @entity229 significantly decreased the rate of acute rejection in well-matched @entity1 . Moreover, this effect was manifest at lower, and therefore less toxic, @entity1140 levels.

Basiliximab induction improves the outcome of renal transplants in XXXX and adolescents.

@entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient'] @entity1071 :: ('MESH:D008232', 'Disease') :: ['post-transplant lymphoproliferative disease'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity1140 :: ('MESH:D016559', 'Chemical') :: ['tacrolimus'] @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids'] @entity1292 :: ('MESH:D009894', 'Disease') :: ['opportunistic infections']
@entity1 :: (9606,Species) :: ['children']
